10X Genomics Bundle
Who Really Owns 10X Genomics?
Uncover the intricate web of 10X Genomics ownership and its impact on the company's future. From its inception to its IPO, understanding the evolution of 10X Genomics' ownership structure is key. This deep dive explores the key players, from founders to institutional investors, shaping the company's strategic direction and financial performance.
The 10X Genomics SWOT Analysis is a great tool to understand the company. Knowing who owns 10X Genomics is crucial for anyone interested in the 10X Genomics stock or understanding the motivations of its executives and major shareholders. This analysis will identify the major shareholders of 10X Genomics, providing insights into the company's governance and long-term strategy, including where 10X Genomics headquarters is located.
Who Founded 10X Genomics?
The company, 10X Genomics, was established in 2012. The founders of 10X Genomics were Serge Saxonov, Ben Hindson, and Kevin Ness. Their combined vision was to develop advanced tools for cellular biology, which was central to the company's inception.
Serge Saxonov, serving as CEO and Co-Founder, previously held a founding director of research role at 23andMe. Ben Hindson, the President and Chief Scientific Officer, also co-founded QuantaLife. Kevin Ness, another co-founder, departed from 10X Genomics in December 2016. The specific equity splits or initial shareholdings at the start are not publicly detailed.
Early funding was crucial for 10X Genomics. The company's initial seed funding in November 2012 was followed by a Series A round in November 2013, totaling $22.4 million. This early backing was essential for fueling its research and development and launching products like the GemCode™ and Chromium™ platforms.
Early Investors
Early investors in 10X Genomics included Venrock, Foresite Capital, and Paladin Capital. These firms participated in the Series B round in January 2015, which raised $55.5 million.
Series C Funding
The Series C financing in March 2016, which raised $55 million, saw Fidelity Management & Research Company as a lead investor. Softbank and JS Capital Management LLC also participated.
Key Executives
Key executives include Serge Saxonov as CEO and Ben Hindson as President and Chief Scientific Officer. Kevin Ness, a co-founder, left the company in December 2016.
Company Focus
10X Genomics focuses on developing tools for cellular biology. These tools are designed to advance research in genomics and related fields.
Product Launch
The company's early products included the GemCode™ and Chromium™ platforms. These platforms were crucial for its initial commercialization efforts.
Company Valuation
As of 2024, the company's valuation and ownership structure continue to evolve. Understanding the current 10X Genomics ownership is key for investors.
Ownership and Investment Insights
Understanding the 10X Genomics ownership structure involves looking at the founders, early investors, and the company's journey through various funding rounds. The company's success is closely tied to its ability to attract and retain key investors. For those interested in the specifics of the 10X Genomics investors and the company's financial backing, further details can be found through public filings and financial reports. The company's focus on cellular biology has positioned it as a key player in the genomics field. For more information on the target market, you can read about the Target Market of 10X Genomics.
- The founders, Serge Saxonov and Ben Hindson, have been instrumental in shaping the company's direction.
- Early investors like Venrock and Fidelity played significant roles in the company's growth.
- The company's products, such as the GemCode™ and Chromium™ platforms, have been pivotal.
- The evolution of 10X Genomics stock and its performance are of interest to investors.
10X Genomics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has 10X Genomics’s Ownership Changed Over Time?
The ownership structure of 10X Genomics, a company focused on advanced genomics technologies, underwent a significant transformation with its Initial Public Offering (IPO) in September 2019. The IPO saw the offering of 10,000,000 shares of Class A common stock at an initial price of $39.00 per share. Prior to the IPO, the company had secured a total of $243 million through eight funding rounds, including a Series D round in January 2019, which valued the company at $1.28 billion. This transition marked a shift from private to public ownership, broadening its investor base and impacting its strategic direction.
As a publicly traded entity, 10X Genomics' ownership is now primarily held by institutional investors, mutual funds, index funds, and individual shareholders. The shift to public markets has provided the company with increased access to capital while also introducing the influence of a broader range of stakeholders. This has influenced strategic decisions and corporate governance through institutional oversight and market dynamics. This evolution is a key aspect of understanding the company's trajectory and its position within the genomics sector. You can also learn more about the Growth Strategy of 10X Genomics.
| Ownership Event | Date | Details |
|---|---|---|
| Series D Funding Round | January 2019 | Valuation of $1.28 billion |
| Initial Public Offering (IPO) | September 2019 | 10,000,000 shares offered at $39.00 per share |
| Institutional Ownership Update | March 31, 2025 | 524 institutional owners holding 134,701,866 shares |
As of March 31, 2025, there are 524 institutional owners and shareholders of 10X Genomics (US:TXG) holding a total of 134,701,866 shares. Major institutional shareholders include ARK Investment Management LLC, which, as of May 14, 2025, reported owning 12,845,713 shares, representing 11.87% ownership. Other significant institutional holders as of March 31, 2025, include Vanguard Group Inc. with 11,118,086 shares (9.03%), Fmr LLC with 10,518,644 shares (8.54%), UBS Asset Management AG with 7,936,556 shares (6.45%), and BlackRock, Inc. with 6,667,822 shares (5.42%). Founder ownership has naturally diluted since the IPO, though Serge Saxonov, Co-Founder and CEO, was reported to own 5.3% of the company's shares as of 2024. Overall insider ownership stood at approximately 7.8% in 2024. The public float as of 2024 was reported as 37,764,219 shares.
Key Takeaways on 10X Genomics Ownership
The ownership structure of 10X Genomics has evolved significantly, from private funding to a public company.
- The IPO in September 2019 was a pivotal event.
- Institutional investors now hold a significant portion of the shares.
- Founder and insider ownership has diluted but remains relevant.
- Understanding the ownership structure is crucial for assessing the company's direction.
10X Genomics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on 10X Genomics’s Board?
The Board of Directors of the 10X Genomics company oversees its strategic direction and governance. Details about the current board members, including their affiliations and roles, are available in the company's filings with the Securities and Exchange Commission (SEC). For instance, the definitive proxy statements (DEF 14A) filed annually provide comprehensive information about the board composition. A DEF 14A filing from April 14, 2025, would offer the most current list of board members.
The board's composition reflects the interests of 10X Genomics' diverse ownership base, which includes both institutional and individual investors. Understanding the board's structure is crucial for anyone interested in the 10X Genomics ownership and how the company is managed. The board's decisions impact 10X Genomics stock and its overall performance.
| Board Member | Title | Affiliation (as of latest filings) |
|---|---|---|
| Serge Saxonov | Co-founder, CEO | Significant Class B shareholder |
| (Information available in DEF 14A filings) | Director | (Information available in DEF 14A filings) |
| (Information available in DEF 14A filings) | Director | (Information available in DEF 14A filings) |
10X Genomics operates with a dual-class share structure, which significantly impacts voting power. Class A common stock has one vote per share, while Class B common stock has ten votes per share. This structure gives disproportionate voting power to Class B shareholders, often including founders and early investors. Following the IPO, Class B shares held approximately 97.7% of the total voting power. This structure allows significant control to be retained by those holding Class B shares, even with a potentially smaller economic interest. For a deeper dive into how the company strategizes, consider reading about the Growth Strategy of 10X Genomics.
Key Takeaways on 10X Genomics Ownership
The board of directors oversees 10X Genomics, representing its diverse ownership. The dual-class share structure grants significant voting power to Class B shareholders, including founders. Understanding the board composition and share structure is essential for assessing the company's governance and potential for 10X Genomics investors.
- Board composition details are found in SEC filings.
- Class B shares hold a disproportionate amount of voting power.
- The CEO, Serge Saxonov, likely holds a significant portion of Class B shares.
- The annual meeting of stockholders on June 3, 2025, addressed matters such as the election of directors.
10X Genomics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped 10X Genomics’s Ownership Landscape?
Over the past few years, the ownership of 10X Genomics has seen notable shifts. As a publicly traded entity, the company's ownership is increasingly dominated by institutional investors. As of March 31, 2025, these investors collectively held 134,701,866 shares of 10X Genomics. Key institutional holders include ARK Investment Management LLC, Vanguard Group Inc., Fmr LLC, UBS Asset Management AG, and BlackRock, Inc. This trend reflects broader market acceptance and inclusion in various investment portfolios, solidifying its position in the market.
In terms of financial performance, 10X Genomics reported total revenue of $610.8 million for 2024, a 1% decrease from the previous year. For the first quarter of 2025, total revenue was $154.9 million, or $138.1 million excluding license and royalty revenue from a settlement, marking a 2% year-over-year decline. The company ended Q1 2025 with $427 million in cash, cash equivalents, and marketable securities. The company anticipates full-year 2025 revenue to be in the range of $610 million to $630 million, projecting 0% to 3% growth over 2024. These financial results can influence investor sentiment and, consequently, ownership dynamics.
| Metric | 2024 | Q1 2025 |
|---|---|---|
| Total Revenue | $610.8 million | $154.9 million |
| Cash, Cash Equivalents, and Marketable Securities (Q1 2025) | N/A | $427 million |
| Projected Revenue Growth (2025) | 0% to 3% | N/A |
Recent developments include an 8% workforce reduction in May 2025, aimed at aligning operational expenses with current economic conditions. The company's product innovation roadmap continues, with plans for new products in single-cell and spatial biology announced in February 2025. Strategic acquisitions, such as Epinomics and Spatial Transcriptomics in 2018, have also shaped the company's direction. For more context, you can explore the Competitors Landscape of 10X Genomics.
10X Genomics Ownership Trends
Institutional investors hold a significant portion of 10X Genomics stock. Key holders include major investment firms. The company's financial performance impacts ownership dynamics.
Key Shareholders of 10X Genomics
Major shareholders include ARK Investment Management LLC, Vanguard Group Inc., and BlackRock, Inc. These firms collectively influence the company's direction. Their investments signal confidence in 10X Genomics' future.
Financial Performance and Ownership
Revenue decreased in 2024 and Q1 2025, impacting investor sentiment. The company's cash position remains strong. Future revenue projections offer insight into potential ownership shifts.
Strategic Moves and Ownership
Workforce reductions and product innovations can influence investor decisions. Acquisitions have shaped the company's strategic direction. These factors indirectly affect who owns 10X Genomics.
10X Genomics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of 10X Genomics Company?
- What is Competitive Landscape of 10X Genomics Company?
- What is Growth Strategy and Future Prospects of 10X Genomics Company?
- How Does 10X Genomics Company Work?
- What is Sales and Marketing Strategy of 10X Genomics Company?
- What is Brief History of 10X Genomics Company?
- What is Customer Demographics and Target Market of 10X Genomics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.